STAT

Meet the doctor who helped inspire a controversial Netflix movie about anorexia

A hotly debated Netflix movie on anorexia, "To the Bone," was written and directed by a former patient of Dr. Richard MacKenzie, who treats eating disorders.

At age 78, Dr. Richard MacKenzie is having his Hollywood moment.

He’s the physician who helped inspire a controversial Netflix movie about anorexia, “To the Bone,” which begins streaming on Friday. The film was written and directed by one of his former patients, Marti Noxon. She has credited MacKenzie with helping her overcome her struggles with anorexia and bulimia.

But “To the Bone” is hardly a faithful portrait of his work. Over a long but under-the-radar career at Children’s Hospital Los Angeles, MacKenzie focused on keeping patients in their homes, rather than admitting them to an inpatient treatment center. He was known for working with his patients, with warmth and sensitivity, to help them identify the issues behind their eating disorders.

His character in “To The Bone,” by contrast, is brusque and edgy — and runs a group home to treat patients with anorexia.

MacKenzie never worked in such  and has watched their the number a decade ago, according to a count published last year. But their treatments are rarely fully covered by insurance and they often offer services, like equine therapy, that aren’t based in evidence.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related